A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome

Table 1 Jadad quality score of randomized, controlled trials included in the meta-analysis

Study	Total score	Withdrawals and dropouts	Blinding	Randomization
Kruis et al[21] 1986	4	0	2	2
Connell[13] 1965	5	1	2	2
Tasman-Jones[22] 1973	4	0	2	2
Berthelot et al[11] 1981	4	0	2	2
Secco et al[19] 1983	4	0	2	2
Enck et al[23] 2005	5	1	2	2
Gilbody et al[24] 2000	4	1	2	1
Inauen et al[25] 1994	3	1	0	2

Table 2 Characteristics of studies comparing mebeverine and placebo included in meta-analysis

Study	Treatment duration (wk)	Dosage		IBS Subtype	Sex (F/M)	Mean age (yr)
		Placebo	Mebeverine			Placebo	Mebeverine
Kruis et al[21] 1986	4-8-12-16	Placebo open branch n = 40	100 mg qid n = 40	All subtype	23/17	F = 43	F = 43
	Wheat bran (12)	Wheat bran 15 g/d n = 40				M = 41	M = 41
Connell[13] 1965	12	n = 20	400 mg/d n = 20	All subtype	25/15	40	40
Tasman-Jones[22] 1973	4	n = 12	400 mg/d n = 12	All subtype	14/10	43	43
Berthelot et al[11] 1981	8	n = 33	400 mg/d n = 36	All subtype	74/37	56	56
Secco et al[19] 1983	4	n = 15	400 mg/d n= 15	All subtype	15/15	45	45
Enck et al[23] 2005	16	Placebo n = 40	n = 40	All subtype		43	36
		Dietary treatment n = 40

Table 3 Outcome results of studies comparing mebeverine with placebo included in meta-analysis

Study	Adverse effect		Relief of abdominal pain		Global or clinical improvement
	Placebo	Mebeverine	Placebo	Mebeverine	Placebo	Mebeverine
Kruis et al[21] 1986	-	-	11/40	9/40	12/40	6/40
Connell[13] 1965	3/22	2/22	-	-	1/22	11/22
Tasman-Jones[22] 1973		-	7/24	15/24	7/24	15/24
Berthelot et al[11] 1981	-	-	-	-	24/33	31/36
Secco et al[19] 1983	-	-	9/15	12/15	-	-
Enck et al[23] 2005	-	-	-	-	16/40	8/40

Table 4 Characteristics of studies comparing two dosage forms of mebeverine included in meta-analysis

Study	Treatment duration (wk)	Dosage		IBS subtype	Sex (F/M)	Mean age (yr)
		Meb 200 mg bid	Meb 135 mg bid			Meb 200 mg	Meb 135 mg
Gilbody et al[24] 2000	4-8	n = 92	n = 92	Abdominal pain predominant	142/42	34	32
Inauen et al[25] 1994	3	n = 24	n = 24	All subtype	36/12	43	37

Meb: Mebeverine.

Table 5 Outcome results of studies comparing two dosage forms of mebeverine included in meta-analysis

Study	Adverse effect		Outcomes of therapeutic efficacy		Relief of abdominal pain		Global or clinical improvement
	Meb 200 mg	Meb 135 mg	Meb 200 mg	Meb 135 mg	Meb 200 mg	Meb 135 mg	Meb 200 mg	Meb 135 mg
Gilbody et al[24] 2000	66/107	63/106	74/92	69/92	65/92	64/92	64/92	59/92
Inauen et al[25] 1994	No serious adverse effect	No serious adverse effects			19/24	23/24	22/24	19/24